Related references
Note: Only part of the references are listed.Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
Toni K. Choueiri et al.
EUROPEAN JOURNAL OF CANCER (2018)
CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma-Results of a phase III noninferiority trial.
Arnaud Mejean et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Escudier et al.
ANNALS OF ONCOLOGY (2016)
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy
Emiliano Calvo et al.
CANCER TREATMENT REVIEWS (2016)
Metastasis therapies for renal cancer
Saeed Dabestani et al.
CURRENT OPINION IN UROLOGY (2016)
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
Naomi B. Haas et al.
LANCET (2016)
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K. Choueiri et al.
LANCET ONCOLOGY (2016)
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
A. Ravaud et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis
James Larkin et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Robert J. Motzer et al.
LANCET ONCOLOGY (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study
Katerina Kubackova et al.
TARGETED ONCOLOGY (2015)
Stereotactic Radiosurgery for Renal Cancer Brain Metastasis: Prognostic Factors and the Role of Whole-Brain Radiation and Surgical Resection
Franziska M. Ippen et al.
JOURNAL OF ONCOLOGY (2015)
Dual VEGF/VEGFR inhibition in advanced solid malignancies Clinical effects and pharmacodynamic biomarkers
Kriti Mittal et al.
CANCER BIOLOGY & THERAPY (2014)
Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era
Simon L. Conti et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Local treatments for metastases of renal cell carcinoma: a systematic review
Saeed Dabestani et al.
LANCET ONCOLOGY (2014)
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
R. J. Motzer et al.
BRITISH JOURNAL OF CANCER (2013)
Brain Metastases from Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors
Arkadiusz Z. Dudek et al.
CLINICAL GENITOURINARY CANCER (2013)
Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
Daniel Y. C. Heng et al.
LANCET ONCOLOGY (2013)
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Distribution of metastatic sites in renal cell carcinoma: a population-based analysis
M. Bianchi et al.
ANNALS OF ONCOLOGY (2012)
Targeting PD-1/PD-L1 interactions for cancer immunotherapy
Laurence Zitvogel et al.
ONCOIMMUNOLOGY (2012)
Evaluation of a new prognostic score (Munich score) to predict long-term survival after resection of pulmonary renal cell carcinoma metastases
Georgios Meimarakis et al.
AMERICAN JOURNAL OF SURGERY (2011)
The Epidemiology of Renal Cell Carcinoma
Borje Ljungberg et al.
EUROPEAN UROLOGY (2011)
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini et al.
LANCET (2011)
Incidence of brain metastases in renal cell carcinoma treated with sorafenib
C. Massard et al.
ANNALS OF ONCOLOGY (2010)
Safety and Efficacy Results of the Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program in North America
Walter M. Stadler et al.
CANCER (2010)
Estimates of cancer incidence and mortality in Europe in 2008
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2010)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
Daniel Y. C. Heng et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
Martin E. Gore et al.
LANCET ONCOLOGY (2009)
Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review
Kiran Gupta et al.
CANCER TREATMENT REVIEWS (2008)
Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy
Elizabeth Cartwright Pfaffenroth et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Familial and Hereditary Renal Cancer Syndromes
Jonathan A. Coleman
UROLOGIC CLINICS OF NORTH AMERICA (2008)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Long-term results of surgical management of pulmonary metastases from renal cell carcinoma
G. Marulli et al.
THORACIC AND CARDIOVASCULAR SURGEON (2006)
Nodal involvement at the time of pulmonary metastasectomy: Experiences in 245 patients
J Pfannschmidt et al.
ANNALS OF THORACIC SURGERY (2006)
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
GV Thomas et al.
NATURE MEDICINE (2006)
Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma?
SC Murthy et al.
ANNALS OF THORACIC SURGERY (2005)
Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma - A stratification tool for prospective clinical trials
BC Leibovich et al.
CANCER (2003)
Long-term results after pulmonary resection of renal cell carcinoma metastases
S Piltz et al.
ANNALS OF THORACIC SURGERY (2002)
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
RC Flanigan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
